Bicara Therapeutics Inc.

BCAX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Assets
Cash & Equivalents $96.6M $323.5M $96.7M $171.7M $436.6M $462.1M $489.7M $520.8M
Accounts Receivable
Inventory
Total Current Assets $503.8M $544.9M $422.1M $297.4M $444.4M $470.8M $502.5M $521.5M
Property, Plant & Equipment $362.0K $346.0K $330.0K $135.0K $117.0K $136.0K $155.0K $130.0K
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $512.2M $553.6M $431.0M $424.7M $453.6M $478.1M $510.0M $524.2M
Liabilities
Accounts Payable
Total Current Liabilities $43.5M $39.3M $28.9M $21.0M $17.2M $19.1M $18.0M $14.5M
Long-Term Debt
Total Liabilities $43.5M $39.6M $29.5M $21.9M $18.4M $19.1M $18.1M $14.6M
Stockholders' Equity
Retained Earnings $-470.6M $-415.2M $-359.0M $-321.6M $-285.3M $-257.9M $-221.0M $-200.1M
Total Stockholders' Equity $468.8M $514.0M $401.5M $402.8M $435.2M $459.0M $491.9M $509.6M
← Newer Page 1 of 2 Older →